Background ExteNET showed that 1 year of neratinib, an irreversible pan-HER tyrosine
kinase inhibitor, significantly improves 2-year invasive disease-free survival after …

Background Neratinib, an irreversible tyrosine-kinase inhibitor of HER1, HER2, and HER4,
has clinical activity in patients with HER2-positive metastatic breast cancer. We aimed to …

Background Neratinib is an irreversible pan-HER tyrosine kinase inhibitor approved for
extended adjuvant treatment in early-stage HER2-positive breast cancer based on the …

Abstract On July 17, 2017, the FDA approved neratinib (NERLYNX; Puma Biotechnology,
Inc.) for the extended adjuvant treatment of adult patients with early-stage HER2 …

Abstract Background The ExteNET trial demonstrated improved invasive disease-free
survival (iDFS) with neratinib, an irreversible pan-HER tyrosine kinase inhibitor, versus …

Background The heterogeneity of breast cancer makes identifying effective therapies
challenging. The I-SPY 2 trial, a multicenter, adaptive phase 2 trial of neoadjuvant therapy …

Background HER2-targeted treatments have improved outcomes in patients with HER2-
positive breast cancer in the neoadjuvant, adjuvant, and metastatic settings; however, some …

Background In our randomised, controlled, phase 3 trial NeOAdjuvant Herceptin (NOAH)
trial in women with HER2-positive locally advanced or inflammatory breast cancer …

Purpose: Despite accumulating evidence on dual blockade of HER2 for locally advanced
HER2-positive breast cancer, no robust evidence supports the addition of pyrotinib to …

An estimated 15–20% of breast cancers overexpress human epidermal growth factor
receptor 2 (HER2/ERBB2/neu). Two small-molecule tyrosine kinase inhibitors (TKIs) …